Intermountain Precision Genomics and Myriad Genetics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification

Intermountain Precision Genomics Laboratory received certification from the New York State Department of Health Clinical Laboratory Evaluation Program. Intermountain Precision Genomics, a service of Intermountain Health, and partner Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, are now certified to offer solid tumor testing to patients in all 50 U.S. states after receiving the New York State Clinical Laboratory Permit. This achievement follows a recent site inspection as part of the New York State Department of Health Clinical Laboratory Evaluation Program.

“This certification by the New York State Department of Health is a testament to this team’s dedication to laboratory safety and quality. The standard for this certification is high, and we’re proud to deliver on that,” said Jason Gillman, Precision Health Operations director, Intermountain Precision Genomics. “Expanding into New York opens the door for Intermountain Precision Genomics and our partners at Myriad Genetics to serve many more patients and healthcare providers than before. We believe our cancer genomics services should be available to every late-stage cancer patient who needs it.”

Intermountain Precision Genomics’ TheraMap®: Solid Tumor genomic test, also offered by Myriad as Precise™ Tumor, analyzes a patient’s tumor DNA to discover what changes, or gene mutations, are causing the cancer. Specialists apply the results to recommend a targeted treatment plan for the patient’s unique tumor profile.

“The NYS certification represents an important step forward in the advancement of precision medicine by increasing access to genetic testing that can help patients with cancer and their providers determine more targeted treatment decisions,” said Michael Lyons, president of Oncology, Myriad Genetics. “Working in close collaboration with Intermountain Precision Genomics, we’re now able to offer the complete Precise Oncology Solutions suite in all 50 states.”

In 2021, Intermountain Health and Myriad announced a collaboration on a comprehensive offering of tests, which includes TheraMap/Precise Tumor. The suite, known as Precise Oncology Solutions, provides oncologists with a complete genetic analysis combining somatic tumor profiling, tissue analysis, and germline testing into one report – helping them establish individualized treatment options for each patient.

TheraMap is the first test in Intermountain Precision Genomics history to obtain this certification. Myriad Genetics was previously certified by the New York State Department of Health for its MyRisk® Hereditary Cancer test and somatic tumor profiling MyChoice® CDx test.

Visit IntermountainHealthcare.org/TheraMap for more information about TheraMap testing, or myriad.com/hcp-precise-oncology-solutions for more on Myriad’s Precise Oncology Solutions.
# # #